Barclays analyst Mark Devries maintains AerCap Holdings (NYSE:AER) with a Overweight and lowers the price target from $72 to $58.
RBC Capital Maintains Sector Perform on BioCryst Pharmaceuticals, Lowers Price Target to $13
RBC Capital analyst Brian Abrahams maintains BioCryst Pharmaceuticals (NASDAQ:BCRX) with a Sector Perform and lowers the price target from $14 to $13.